Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Marcus Smith Noel"'
Autor:
Howard S. Hochster, Ignacio Garrido-Laguna, Florencia Jalikis, Philip A. Philip, Marc R. Radke, Jordan Berlin, Mai Duong, Jennifer Marie Suga, Michael J. Pishvaian, Marcus Smith Noel, Katherine A. Guthrie, Shay Bellasea, Dana Backlund Cardin, E. Gabriela Chiorean, Andrew M. Lowy, Elizabeth M. Swisher
Publikováno v:
Clinical Cancer Research. 27:6314-6322
Purpose: PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::607d3838a02c0658322b6e6710627752
https://doi.org/10.1158/1078-0432.ccr-21-1789
https://doi.org/10.1158/1078-0432.ccr-21-1789
Autor:
Carlos L. Arteaga, Larry Rubinstein, Lisa M. McShane, Douglas B. Johnson, Fengmin Zhao, Robert Gray, Keith T. Flaherty, Stanley R. Hamilton, David R. Patton, Gregory J. Riely, Alice P. Chen, Barbara A. Conley, Marcus Smith Noel, John J. Wright, Lyndsay Harris, Shuli Li, Edith P. Mitchell, Helen X. Chen, Peter J. O'Dwyer, Mickey Williams
Publikováno v:
Clin Cancer Res
Purpose: Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with BRAF mutations outside the V600 locus, and in BRAF fusions. Thus, Subprotocol R of the NCI-MATCH study tested the MEK inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffe30f97fe3240ba70f95c449b980dfb
https://doi.org/10.1158/1078-0432.ccr-19-3443
https://doi.org/10.1158/1078-0432.ccr-19-3443
Autor:
Julie Switzky, Gerald Steven Falchook, Monica M. Mita, Russell Z. Szmulewitz, Swamy Yeleswaram, Wael A. Harb, Moshe Talpaz, Shilpa Gupta, Razelle Kurzrock, Justin M. Watts, Julio Antonio Peguero, Gongfu Zhou, Phillip Liu, Amitkumar Mehta, Marcus Smith Noel, Seth Rosen, Ryan D. Cassaday, Patricia LoRusso, Catherine C. Coombs, Fred Zheng, Sarina Anne Piha-Paul, David Smith
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 6
Clin Cancer Res
Clin Cancer Res
Purpose: Bromodomain and extraterminal (BET) proteins are key epigenetic transcriptional regulators, inhibition of which may suppress oncogene expression. We report results from 2 independent first-in-human phase 1/2 dose–escalation and expansion,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50020508bf4925094286db6a47e8069d
https://doi.org/10.1158/1078-0432.ccr-18-4071
https://doi.org/10.1158/1078-0432.ccr-18-4071
Autor:
Reetu Mukherji, Shravanthy Suguru, Jerry Xiao, Xue Geng, Hongkun Wang, Marcus Smith Noel, Aiwu Ruth He, Benjamin Adam Weinberg, John Marshall, Seema Agarwal
Publikováno v:
Journal of Clinical Oncology. 41:805-805
805 Background: Studying CTC cultures (cx) ex-vivo can provide valuable insights into cancer metastases (mets). However, current immunoaffinity- and size-based-methods used to isolate and expand these cells have low success rates for culturing CTCs (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b32d51c79d27bc7110f6372096667e0e
https://doi.org/10.1200/jco.2023.41.4_suppl.805
https://doi.org/10.1200/jco.2023.41.4_suppl.805
Autor:
Kevin Fiscella, Marcus Smith Noel
Publikováno v:
Health Equity, Vol 3, Iss 1, Pp 532-540 (2019)
Health Equity
Health Equity
Purpose: Pancreatic cancer remains a major health concern; in the next 2 years, it will become the second leading cause of cancer deaths in the United States. Health disparities in the treatment of pancreatic cancer exist across many disciplines, inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a98dd856253816c26f83249d3b0392f
https://www.liebertpub.com/doi/full/10.1089/HEQ.2019.0057
https://www.liebertpub.com/doi/full/10.1089/HEQ.2019.0057
Autor:
Alexander G. Vandell, Giuseppe Del Priore, Damian Stega, Marcus Smith Noel, Jeanetta Stega, Steve Hoffman
Publikováno v:
Investigational New Drugs
Summary Purpose SM-88 (D,L-alpha-metyrosine; racemetyrosine) is a novel anti-cancer agent, used with melanin, phenytoin, and sirolimus (SMK Therapy). This pilot first-in-human study characterized the safety, tolerability, and efficacy of SMK Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecf6f7ae3aaeb88efaf8190172d54f7
https://doi.org/10.1007/s10637-019-00758-8
https://doi.org/10.1007/s10637-019-00758-8
Autor:
Larissa K. Temple, Andrea Baran, Marcus Smith Noel, Aram F. Hezel, John Hu, Mohamedtaki Abdulaziz Tejani, Gradon Nielsen, Matthew Preslar, Danielle Wallace, Richard F. Dunne, Fergal J. Fleming, Franklin Li
Publikováno v:
Clinical colorectal cancer. 19(3)
Background National Comprehensive Cancer Network guidelines for the treatment of locally advanced rectal cancer advocate neoadjuvant chemoradiotherapy followed by total mesorectal excision and adjuvant chemotherapy (AC). The aim of this retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::967ce0050da9dca5bb7a74a7b6758a89
https://pubmed.ncbi.nlm.nih.gov/32409226
https://pubmed.ncbi.nlm.nih.gov/32409226
Autor:
Chao Yin, John Marshall, Laura Macke, Kerrie Bouker, Aiwu Ruth He, Benjamin Adam Weinberg, Louis M. Weiner, Hongkun Wang, Nabeel Badri, Nigel Biswas-Baldwin, Frank Hoke, Hagop Youssoufian, Iman El-Hariry, Marcus Smith Noel
Publikováno v:
Journal of Clinical Oncology. 40:581-581
581 Background: The prognosis for advanced metastatic pancreatic adenocarcinoma remains dismal with median survival of 12-15 months in most recent trials, highlighting the urgent need for novel therapeutic agents. mFOLFIRINOX remains the standard of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8689d8291c0364012ee610d6ffc11fab
https://doi.org/10.1200/jco.2022.40.4_suppl.581
https://doi.org/10.1200/jco.2022.40.4_suppl.581
Autor:
Marcus Smith Noel, Steve Wong, Vincent J. Picozzi, Harry Staszewski, Dae Won Kim, Marion L. Hartley, Maria Loushin, Shabnam Stanicky, Justin Lau, Semmie Kim, Jan Van Tornout, Philip Agop Philip, Vincent Chung, Allyson J. Ocean, Andrea wang-gillam
Publikováno v:
Journal of Clinical Oncology. 40:585-585
585 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a poor prognosis in refractory patients (pts). SM-88 Regimen, which comprises oral SM-88 (racemetyrosine, TYME Inc) plus 10mg methoxsalen, 50mg phenytoin, and 0.5mg sirolimus (MP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b11380d942275335fd2bc0f5fdbd8442
https://doi.org/10.1200/jco.2022.40.4_suppl.585
https://doi.org/10.1200/jco.2022.40.4_suppl.585
Autor:
Chao Yin, Samantha Ann Armstrong, Seema Agarwal, Hongkun Wang, Marcus Smith Noel, Benjamin Adam Weinberg, John Marshall, Aiwu Ruth He
Publikováno v:
Journal of Clinical Oncology. 40:452-452
452 Background: Unresectable cholangiocarcinoma (CCA) remains a cancer of dismal prognosis as these tumors tend to be highly chemotherapy-refractory, providing patients (pts) a median survival of only around nine months. We herein provide an interim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ad129287ceaaafdd9cf737e729b1014
https://doi.org/10.1200/jco.2022.40.4_suppl.452
https://doi.org/10.1200/jco.2022.40.4_suppl.452